CR20210006A - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
CR20210006A
CR20210006A CR20210006A CR20210006A CR20210006A CR 20210006 A CR20210006 A CR 20210006A CR 20210006 A CR20210006 A CR 20210006A CR 20210006 A CR20210006 A CR 20210006A CR 20210006 A CR20210006 A CR 20210006A
Authority
CR
Costa Rica
Prior art keywords
estrogen receptor
selective estrogen
receptor degraders
degraders
serds
Prior art date
Application number
CR20210006A
Other languages
English (en)
Inventor
Daniel Jon Sall
Jeffrey Daniel Cohen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67480324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210006A publication Critical patent/CR20210006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

<p>Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula sales farmacéuticamente aceptables, composiciones farmacéuticas, usos y métodos de uso de estos.</p>
CR20210006A 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrógeno CR20210006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
US201962825172P 2019-03-28 2019-03-28
PCT/US2019/041342 WO2020014440A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
CR20210006A true CR20210006A (es) 2021-02-05

Family

ID=67480324

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210006A CR20210006A (es) 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrógeno

Country Status (33)

Country Link
US (1) US20210260052A1 (es)
EP (1) EP3820874B1 (es)
JP (1) JP7085056B2 (es)
KR (1) KR102577142B1 (es)
CN (1) CN112424205B (es)
AU (1) AU2019299952B2 (es)
BR (1) BR112020025381A2 (es)
CA (1) CA3105491C (es)
CL (1) CL2021000046A1 (es)
CO (1) CO2021000041A2 (es)
CR (1) CR20210006A (es)
DK (1) DK3820874T3 (es)
EC (1) ECSP21001786A (es)
ES (1) ES2932867T3 (es)
FI (1) FI3820874T3 (es)
HR (1) HRP20230080T1 (es)
HU (1) HUE061032T2 (es)
IL (1) IL279990B2 (es)
JO (1) JOP20210004A1 (es)
LT (1) LT3820874T (es)
MD (1) MD3820874T2 (es)
MX (1) MX2021000377A (es)
NZ (1) NZ771719A (es)
PE (1) PE20211245A1 (es)
PH (1) PH12021550048A1 (es)
PL (1) PL3820874T3 (es)
PT (1) PT3820874T (es)
RS (1) RS63876B1 (es)
SA (1) SA521421006B1 (es)
SG (1) SG11202100145YA (es)
SI (1) SI3820874T1 (es)
UA (1) UA125890C2 (es)
WO (1) WO2020014440A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
US11730726B2 (en) 2018-07-11 2023-08-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR20240052933A (ko) * 2021-08-31 2024-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 모노사이클릭 피리딘 유도체를 제조하기 위한 방법
US11926634B2 (en) 2022-02-01 2024-03-12 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
WO2024042157A1 (en) 2022-08-25 2024-02-29 Sanofi Novel substituted quinoline and tetrahydronaphthalene carboxylic acid derivatives and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
DE60210283T2 (de) 2001-05-22 2006-11-09 Eli Lilly And Co., Indianapolis 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
US7329654B2 (en) 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
EP1497277A1 (en) 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
DE20301728U1 (de) * 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US20090023917A1 (en) * 2004-01-22 2009-01-22 Eli Lilly And Company Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
BRPI0514974A (pt) * 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
JP6768711B2 (ja) * 2015-05-26 2020-10-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 複素環式エストロゲン受容体モジュレーター及びその使用
EP3440067B1 (en) * 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
JP7229162B2 (ja) * 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
WO2020014440A1 (en) 2020-01-16
UA125890C2 (uk) 2022-06-29
JP7085056B2 (ja) 2022-06-15
LT3820874T (lt) 2023-02-10
DK3820874T3 (da) 2022-12-12
MD3820874T2 (ro) 2023-05-31
MX2021000377A (es) 2021-03-25
AU2019299952A1 (en) 2021-01-21
HRP20230080T1 (hr) 2023-03-17
KR20210018460A (ko) 2021-02-17
IL279990B1 (en) 2023-03-01
PL3820874T3 (pl) 2023-02-06
BR112020025381A2 (pt) 2021-03-09
CA3105491C (en) 2023-09-05
SI3820874T1 (sl) 2023-02-28
KR102577142B1 (ko) 2023-09-12
AU2019299952B2 (en) 2022-06-16
CO2021000041A2 (es) 2021-01-18
EP3820874B1 (en) 2022-11-30
CL2021000046A1 (es) 2021-06-25
PH12021550048A1 (en) 2021-09-20
PE20211245A1 (es) 2021-07-13
JP2021530486A (ja) 2021-11-11
RS63876B1 (sr) 2023-02-28
FI3820874T3 (fi) 2023-03-06
SG11202100145YA (en) 2021-02-25
EP3820874A1 (en) 2021-05-19
ECSP21001786A (es) 2021-02-26
SA521421006B1 (ar) 2023-02-08
NZ771719A (en) 2024-02-23
JOP20210004A1 (ar) 2021-01-10
IL279990A (en) 2021-03-01
HUE061032T2 (hu) 2023-05-28
ES2932867T3 (es) 2023-01-27
PT3820874T (pt) 2023-01-06
CA3105491A1 (en) 2020-01-16
CN112424205B (zh) 2023-10-31
US20210260052A1 (en) 2021-08-26
IL279990B2 (en) 2023-07-01
CN112424205A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
CR20210006A (es) Degradadores selectivos del receptor de estrógeno
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
PH12021550049A1 (en) Selective estrogen receptor degraders.
NZ747259A (en) Soluble c5ar antagonists
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
PH12017501816A1 (en) Azabensimidazoles and their use as amp a receptor modulators
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
TN2020000009A1 (en) Estrogen receptor modulators
PH12017501280A1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
MX2023010823A (es) Degradadores selectivos del receptor de estrogeno.
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
EA201991734A1 (ru) Модуляторы рецептора эстрогена